Annual Report

Overview

The report presents Cloudbreak Pharma as a clinical-stage ophthalmology biotechnology group with nine proprietary drug candidates, including five clinical-stage and four pre-clinical candidates. During 2025, CBT-001 completed recruitment across five jurisdictions with 660 patients enrolled, while CBT-004 completed Phase 2 and reached agreement with the FDA on its Phase 3 design. The company listed on the Hong Kong Stock Exchange in July 2025 and reported approximately HK$524.6 million of net IPO proceeds. It also disclosed environmental policies and referred readers to a separate ESG report dated 30 March 2026.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 30 March 2026
Language: English, Chinese
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services